Tag: Quality Systems

Understanding Method Development Instability in Early Stages and Its Regulatory Implications Method development is a critical phase in pharmaceutical research and development, where the stability of methods significantly affects regulatory…

Addressing Poor Justification of Design Space During Manufacturing Transfers to Mitigate GMP Risks In the pharmaceutical industry, ensuring that the design space for a product is adequately justified during the…

Understanding Method Development Instability During Comparability Assessment: CAPA Strategies for Development Lifecycle In the highly regulated pharmaceutical industry, method development instability during a comparability assessment can lead to significant challenges…

Assessing the Impact of Excipient Variability During Comparability: An Investigation Framework In the pharmaceutical industry, the variability of excipients can present significant challenges, especially during comparability assessments. These assessments are…

“`html Addressing Uncaptured Process Knowledge During Pilot Scale for Effective Tech Transfer In the pharmaceutical manufacturing environment, capturing comprehensive process knowledge during the pilot scale can often be overlooked, leading…

Addressing Poor Justification of Design Space During Scale-Up for Effective Tech Transfer In pharmaceutical manufacturing, effectively managing scale-up processes while justifying design space is crucial for ensuring successful tech transfers.…

Understanding the Impact of Excipient Variability During Scale-Up and Its Regulatory Implications In the pharmaceutical industry, the transition from laboratory-scale development to full-scale manufacturing can present various challenges, particularly concerning…

Assessing Process Knowledge Gaps During Comparability Evaluations to Mitigate GMP Risks In the evolving landscape of pharmaceutical development, ensuring that all critical process knowledge is captured during comparability assessments is…

Identifying Scale-up Risks During Pilot Scale: Investigative Action for GMP Compliance In pharmaceutical manufacturing, the transition from pilot to commercial scale can present significant challenges—particularly when risks encountered during piloting…

“`html Exploring Method Development Instability During Comparability Assessment: Addressing Downstream GMP Risks Method development instability during comparability assessments can pose significant risks to Good Manufacturing Practice (GMP) compliance in pharmaceutical…

Addressing the Gap in Process Knowledge During Transfer to Manufacturing: A CAPA Framework In pharmaceutical manufacturing and development, the transition of process knowledge from R&D to manufacturing is critical. When…

Understanding and Addressing Poor Justification of Design Space in Early Development The success of a pharmaceutical product often hinges on well-defined and justified design space during its early development stages.…